Skip to main content
Equibles

CITADEL ADVISORS LLC

Position in RXRX — Recursion Pharmaceuticals, Inc.

CIK 1423053 MIAMI, FL
Back to RXRX Full portfolio

Position in RXRX

as of Mar 31, 2026 · filed May 15, 2026
Position Value
$1,917,703
-$15,382,992 QoQ
Shares Held
624,659
-85.2% QoQ
Ownership
0.118%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2021
20 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in RXRX Over Time

Shares Held

Position Value (USD)

Derivatives in RXRX

reported options exposure · as of Mar 31, 2026
CallValue
$3,100,086
CallShares
1,009,800
PutValue
$2,452,623
PutShares
798,900

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Mar 31, 2026

CITADEL ADVISORS LLC holds $5,784,241,435 across 374 Biotechnology names. RXRX ranks #196 (0.0% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 INSM
INSMED Inc
 2,182,571 $356,894,009
2 ONC
BeOne Medicines Ltd.
 1,032,298 $306,561,536
3 BMRN
Biomarin Pharmaceutical Inc
 4,512,634 $254,918,694
4 JAZZ
Jazz Pharmaceuticals plc
 1,259,444 $238,097,887
5 MDGL
Madrigal Pharmaceuticals, Inc.
 453,843 $237,573,195
6 BBIO
BridgeBio Pharma, Inc.
 3,173,940 $235,696,783
7 TERN
Terns Pharmaceuticals, Inc.
 3,218,810 $169,695,662
8 PTGX
Protagonist Therapeutics, Inc
 1,551,900 $163,570,260

All Filings in RXRX

Export CSV
50 filing rows on record
Report Date Value (USD) Shares
2026-03-31 $1,917,703 624,659
2026-03-31 $3,100,086 1,009,800
2026-03-31 $2,452,623 798,900
2025-12-31 $8,039,304 1,965,600
2025-12-31 $8,093,292 1,978,800
2025-12-31 $17,300,695 4,229,999
2025-09-30 $9,482,328 1,943,100
2025-09-30 $5,320,176 1,090,200
2025-09-30 $6,581,577 1,348,684
2025-06-30 $8,680,743 1,715,562
2025-06-30 $6,651,633 1,314,552
2025-06-30 $3,536,671 698,947
2025-03-31 $14,048,711 2,655,711
2025-03-31 $7,193,791 1,359,885
2025-03-31 $1,966,753 371,787
2024-12-31 $18,517,309 2,739,247
2024-12-31 $3,478,919 514,633
2024-12-31 $8,847,785 1,308,844
2024-09-30 $3,668,653 556,700
2024-09-30 $1,972,387 299,300
2024-09-30 $1,543,529 234,223
2024-06-30 $1,923,000 256,400
2024-06-30 $5,588,092 745,079
2024-06-30 $4,125,750 550,100
2024-03-31 $2,205,364 221,200
2024-03-31 $3,393,528 340,374
2024-03-31 $2,365,881 237,300
2023-12-31 $1,264,052 128,200
2023-12-31 $833,170 84,500
2023-12-31 $359,830 36,494
2023-09-30 $2,318,638 303,090
2023-09-30 $638,775 83,500
2023-09-30 $602,055 78,700
2023-06-30 $59,013 7,900
2023-06-30 $5,511,052 737,758
2023-06-30 $187,497 25,100
2023-03-31 $148,074 22,200
2023-03-31 $4,038,784 605,515
2023-03-31 $153,410 23,000
2022-12-31 $147,261 19,100
2022-12-31 $5,945,566 771,150
2022-12-31 $10,023 1,300
2022-09-30 $202,160 19,000
2022-09-30 $5,339,896 501,870
2022-09-30 $122,360 11,500
2022-06-30 $234,432 28,800
2022-06-30 $123,728 15,200
2022-06-30 $2,502,007 307,372
2022-03-31 $151,076 21,100
2022-03-31 $6,515,384 909,970

Report a Problem

Category
Description
Email (optional, for follow-up)